Well, this is the main issue of the topic. So I think that in the incomplete, well, the successful re-canalization, but not complete re-canalization, we should discover the right adjunctive therapy. It may be tirofiban or it may be intra-arterial fibrinolysis. And maybe we have to study more and find which approach should be used. Up to now, the two approaches with the most accumulated evidence are the intra-arterial fibrinolysis and the tirofiban...
Well, this is the main issue of the topic. So I think that in the incomplete, well, the successful re-canalization, but not complete re-canalization, we should discover the right adjunctive therapy. It may be tirofiban or it may be intra-arterial fibrinolysis. And maybe we have to study more and find which approach should be used. Up to now, the two approaches with the most accumulated evidence are the intra-arterial fibrinolysis and the tirofiban. And I think that there are scenarios of patients that should benefit from these approaches. And in the case of tandem lesion stroke, I think that the ATILA trial that is going to be mentioned in this presentation, it’s a good approach because the tirofiban has demonstrated to us that it reduced the reocclusion. We have to face some concerns about the safety and the functional outcome, but this is the first step. And I hope that it’s coming different trials in the future to improve our results. So, of course, I support the tirofiban in the tandem lesion stroke and in the other scenario in which we face every day, which are the incomplete reorganization, maybe the intra-arterial fibrinolysis and the tirofiban for some population of stroke patients should be benefited. I think that we need more clinical trials. And the coming evidence that we would receive in the next year would be the best strategy. And try to make more homogeneous all the protocols regarding the intra-arterial fibrinolysis and the tirofiban in the tendon lesion stroke approaches because some of the trials use the stent, some others don’t use. So we have to keep improving our selection criteria and trying to make more homogeneous the protocols of the trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.